Telormedix SA
Targeted immunity in the treatment of cancer and other disea
Telormedix is a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
08.12.2014
Orphan Drug Status Granted to Telormedix´ lead product (startupticker.ch)
19.05.2014
Telormedix’s Cancer Drug Successfully Completes Phase II Trials (startupticker.ch)
02.12.2013
Telormedix Raises CHF 6 M in Series B Financing Round (startupticker.ch)
07.08.2013
Telormedix Receives EU Funding (startupticker.ch)
07.01.2013
Telormedix: Go-ahead for Phase II trials (startupticker.ch)
No milestones
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Telormedix SA
Targeted immunity in the treatment of cancer and other disea
Website:
www.telormedix.com
UroGen Pharma
Headquarter:
Bioggio
Foundation Date:
October 2007
Technology:
- Biotech
Sectors:
- Cancer
Support received
